Histamine metabolism in mastocytosis patients treated with interferon alpha-2b.
Granerus
G
G
Department of Clinical Physiology, University Hospital, Linköping, Sweden.
Lönnqvist
B
B
Roupe
G
G
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D005260:Female; D006632:Histamine / Q000378:metabolism*; D006801:Humans; D007093:Imidazoles / Q000652:urine; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects*; D008415:Mastocytosis / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D008875:Middle Aged; D011994:Recombinant Proteins; D012016:Reference Values; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D007093:Imidazoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C002667:methylimidazoleacetic acid; D006632:Histamine